Newsletters

[BioRestorative Therapies, Inc.] BioRestorative Therapies, Inc. announced blinded data from its Phase II clinical trial evaluating hypoxic-cultured MSCs for the treatment of chronic lumbar disc disease, with 50% or more of treated patients reporting improvements >50% across key pain and functional outcome measures and no adverse events related to dose-limiting toxicities.

[Moffitt Cancer Center] At Moffitt Cancer Center, there are countless doctors, researchers, and clinicians on the frontlines caring for patients every day.

[Cell Death & Disease] Scientists identified a novel molecular axis centered on circRNA-0010220 within bone marrow MSC-derived extracellular vesicles that drives osteosarcoma aggressiveness.

[Stem Cell Research & Therapy] This study aimed to elucidated senescence-related phenotypic alterations and regulatory mechanisms in human tonsil-derived MSCs.

[Biofabrication] Investigators reported a 3D cartilaginous construct by encapsulation of spheroids of human umbilical cord–derived MSCs within gelatin methacryloyl hydrogels where the mineral–coated fibers were integrated within the spheroid for localized ion delivery, thereby alleviating diffusion limitations.

[Advanced Science] The authors review current advances in MSC-based therapies for immune-related disorders, emphasizing Phase III and IV clinical trials and therapies approved by global regulatory agencies.

[Journal of Translational Medicine] MSCs and their cell-free secretome represent a promising therapeutic platform for neurological disorders by directly targeting neuroinflammation. Future progress will depend on developing next-generation, potentially bioengineered, secretome-based products with defined potency to bring this regenerative strategy from the laboratory to the clinic.

[Cell Death & Disease] Researchers investigated the function of 14-3-3γ in the osteogenic differentiation of human adipose-derived MSCs. Using an adenoviral system, they knocked down 14-3-3γ and assessed osteogenic markers.

[Cell Death & Disease] Investigators reported the development of a novel dual cellular immunotherapy in which human umbilical cord-derived MSCs are co-administered with CD19 CAR T-cells.

[Nature Communications] The authors established a lineage-traceable genetically engineered mouse model with controlled activation of hemizygous Dicer1 RNase IIIb mutation in Hic1+ mesenchymal stromal cells.

[Premier Anesthesia] Premier Anesthesia announced a new partnership with City of Hope^® Phoenix Cancer Center, marking its expansion into the Arizona healthcare market and enhancing its commitment to comprehensive cancer care.

[Signal Transduction and Targeted Therapy] Researchers developed DC551040, an irreversible covalent lysine demethylase 1 (LSD1) inhibitor characterized by high potency, excellent selectivity, and oral availability, which exhibits robust anti-AML effects in vitro and in vivo and is currently progressing through Phase I clinical trials.